Volume 152, Issue 3, Pages (March 2019)

Slides:

Advertisements

Similar presentations

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Advertisements

CCO Independent Conference Coverage

LUX-Lung 6 clinical trial

Table 1. Patient Characteristics

Volume 144, Issue 1, Pages (January 2017)

PARP INHIBITION IN OVARIAN CANCER

LUX-Lung 3 clinical trial

Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero,

Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective survey Lazzaro Repetto Critical.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Volume 18, Issue 4, Pages (January 2017)

Using Laboratory Test Results at Hospital Admission to Predict Short-term Survival in Critically Ill Patients With Metastatic or Advanced Cancer Lee.

Claudia Sommer, MD, Giorgio Cruccu, MD

Volume 63, Issue 2, Pages (February 2013)

Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.

Volume 150, Issue 1, Pages (July 2018)

Volume 148, Issue 1, Pages (January 2018)

Are patients willing to travel for better ovarian cancer care?

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

Volume 150, Issue 3, Pages (September 2018)

Pain in cancer survivors; filling in the gaps

Volume 149, Issue 2, Pages (May 2018)

Fatigue in Gynecological Cancer Patients During and After Anticancer Treatment Gillian Prue, PhD, James Allen, PhD, Jacqueline Gracey, PhD, Jane Rankin,

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Volume 147, Issue 1, Pages 3-10 (October 2017)

Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians) Carsten Nieder, Thomas A.

The efficacy of mTORC1/2 inhibition on ovarian cancer stem cells

Volume 141, Issue 2, Pages (May 2016)

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Volume 151, Issue 1, Pages (October 2018)

The development and use of vascular targeted therapy in ovarian cancer

Volume 145, Issue 2, Pages (May 2017)

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

MAINTENANCE THERAPY WITH PARP INHIBITORS

Dr Axel Walther Head of Research Bristol Cancer Institute UK

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 147, Issue 2, Pages (November 2017)

Volume 143, Issue 2, Pages (November 2016)

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Volume 152, Issue 1, Pages (January 2019)

Author's Response Journal of Pain and Symptom Management

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study Cesare Gridelli, MD,

Volume 147, Issue 1, Pages (October 2017)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

Volume 152, Issue 1, Pages (January 2019)

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older Yuh-Min Chen,

Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III.

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta- analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in.

Volume 147, Issue 2, Pages (November 2017)

Volume 147, Issue 3, Pages (December 2017)

Volume 150, Issue 3, Pages (September 2018)

Volume 130, Issue 1, Pages (July 2013)

Volume 151, Issue 1, Pages (October 2018)

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

Comparison of Docetaxel- and Vinca Alkaloid–Based Chemotherapy in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis of.

Survival without Common Toxicity Criteria Grade 3/4 Toxicity for Pemetrexed Compared with Docetaxel in Previously Treated Patients with Advanced Non-small.

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed D.

Claudia Sommer, MD, Giorgio Cruccu, MD

Volume 75, Issue 1, Pages (January 2009)

Physical Function in Patients with Cancer

Volume 154, Issue 1, Pages (July 2019)

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

Fatigue in Gynecological Cancer Patients During and After Anticancer Treatment Gillian Prue, PhD, James Allen, PhD, Jacqueline Gracey, PhD, Jane Rankin,

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

Volume 152, Issue 3, Pages 560-567 (March 2019) Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial Michel Fabbro, Kathleen N. Moore, Anne Dørum, Anna V. Tinker, Sven Mahner, Isabel Bover, Susana Banerjee, Germana Tognon, Frederic Goffin, Ronnie Shapira-Frommer, Robert M. Wenham, Kristina Hellman, Diane Provencher, Philipp Harter, Isabel Palacio Vázquez, Philippe Follana, Mario J. Pineda, Mansoor R. Mirza, Sebastien J. Hazard, Ursula A. Matulonis Gynecologic Oncology Volume 152, Issue 3, Pages 560-567 (March 2019) DOI: 10.1016/j.ygyno.2018.12.009 Copyright © 2018 The Authors Terms and Conditions

Fig. 1 (A) Progression-free survival with niraparib by treatment arm, age group, and cohort, and (B) hazard ratios by cohort in the niraparib arm by age. CI, confidence interval; gBRCAmut, germline breast cancer susceptibility gene mutation; PFS, progression-free survival. Gynecologic Oncology 2019 152, 560-567DOI: (10.1016/j.ygyno.2018.12.009) Copyright © 2018 The Authors Terms and Conditions

Fig. 2 Most frequent TEAEs in the niraparib arm by age. TEAEs, treatment-emergent adverse events. aIncludes reports of thrombocytopenia and decreased platelet count; bIncludes fatigue, malaise, lethargy, and asthenia; cIncludes reports of anemia and decreased hemoglobin counts; dIncludes reports of neutropenia, decreased neutrophil count, and febrile neutropenia. Gynecologic Oncology 2019 152, 560-567DOI: (10.1016/j.ygyno.2018.12.009) Copyright © 2018 The Authors Terms and Conditions

Fig. 3 Incidence of AESI in the niraparib arm by age. AESI, adverse event of special interest. aIncludes reports of thrombocytopenia and decreased platelet count; bIncludes fatigue, malaise, lethargy, and asthenia; cIncludes reports of anemia and decreased hemoglobin counts; dIncludes leukopenia, white blood cell count decreased, lymphocyte count decreased, lymphopenia, monocyte count decreased, and neutropenia event; eIncludes reports of neutropenia, decreased neutrophil count, and febrile neutropenia; fIncludes myelodysplastic syndrome and pancytopenia; gIncludes overdose and accidental overdose. Gynecologic Oncology 2019 152, 560-567DOI: (10.1016/j.ygyno.2018.12.009) Copyright © 2018 The Authors Terms and Conditions

Fig. 4 Individual Functional Assessment of Cancer Therapy–Ovarian Symptoms Index measures over time. Symptoms include (A) fatigue, (B) pain, (C) nausea, (D) vomiting, (E) bloating, (F) cramps, and (G) worry. BL, baseline. Gynecologic Oncology 2019 152, 560-567DOI: (10.1016/j.ygyno.2018.12.009) Copyright © 2018 The Authors Terms and Conditions

Fig. 4 Individual Functional Assessment of Cancer Therapy–Ovarian Symptoms Index measures over time. Symptoms include (A) fatigue, (B) pain, (C) nausea, (D) vomiting, (E) bloating, (F) cramps, and (G) worry. BL, baseline. Gynecologic Oncology 2019 152, 560-567DOI: (10.1016/j.ygyno.2018.12.009) Copyright © 2018 The Authors Terms and Conditions